Close Menu

NEW YORK – Clinical-stage precision medicine company MapKure and its joint owners BeiGene and SpringWorks Therapeutics said Thursday that they have kicked off a Phase I clinical trial evaluating BGB-3245, an investigational BRAF inhibitor. 

The trial will enroll up to 69 patients with solid tumors who harbor BRAF mutations and are likely to respond to a RAF dimer inhibitor. The companies have dosed their first patient in Australia and will soon expand the study to sites in the US.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.